Mounjaro weight loss results: what you should expect to lose, weekly and monthly timelines

Mounjaro is the brand name for tirzepatide. In the UK, it is licensed for weight management in adults with obesity, or in adults with overweight and at least one weight-related health condition, when used alongside a reduced-calorie diet and increased physical activity. [1] [2]The clearest answer to “how much weight can you lose on Mounjaro?” comes from the SURMOUNT clinical trial programme. These were controlled studies, so they are more reliable than before-and-after photos, individual reviews or social media reports.

In SURMOUNT-1, which included adults with obesity or overweight but not type 2 diabetes, average weight loss at 72 weeks was 16.0% with 5 mg, 21.4% with 10 mg and 22.5% with 15 mg, compared with 2.4% with placebo. At the 15 mg dose, 62.9% of participants lost at least 20% of their starting body weight. [1]

That does not mean every patient should expect the highest figure. Trial averages combine people with different starting weights, health profiles, side effects, dose tolerance and adherence. A useful way to read the data is: Mounjaro can produce large average losses in suitable people, but the personal result is built gradually and needs clinical monitoring.

Mounjaro weight loss results in major studies

Note: these are group averages from controlled studies. They are benchmarks, not guaranteed individual results.

What about week 1, one month, three months and six months?

Early weight changes are usually less reliable than longer trends. A change in appetite can happen before a clear change on the scales, and a single week can be affected by fluid, bowel habits, salt intake, menstrual cycle changes, exercise soreness, illness and weighing conditions.

• Week 1 to week 4: the usual starting dose is 2.5 mg once weekly. This is an introductory dose, not one of the usual adult maintenance doses. Some people notice appetite changes early, while others notice very little at this stage. [1]
• One month: the first month is too early to judge your full response. The dose may only just be moving from 2.5 mg to 5 mg if treatment is suitable and tolerated. [1]
• Three months: the trend becomes more useful than individual weekly readings. Prescribers may look at whether weight, side effects, eating pattern and dose escalation are moving in a safe direction.
• Six months: official product information says that if a patient has been unable to lose at least 5% of initial body weight 6 months after titrating to the highest tolerated dose, a decision is needed on whether to continue treatment, considering the individual benefits and risks. [1]
• One year and beyond: the strongest trial data are measured over longer periods, including 72-week studies. Some people continue to lose weight after the first few months; others slow down or plateau and need review.

A slow first month does not automatically mean Mounjaro is not working. It may reflect the starting dose, dose escalation stage, side-effect management, weighing noise or the need to review nutrition and routine. The safer question is not “why am I failing?” but “what needs checking?

Paul John MPharm, IP

Why Mounjaro weight loss results vary from person to person

Two people can take the same medicine and lose weight at different speeds. That is not unusual. Mounjaro affects appetite, fullness, food cravings and glucose regulation, but it still sits within a wider clinical picture.

• Dose and time on treatment: results from 2.5 mg in the first month should not be compared with 72-week trial outcomes at maintenance doses.
• Tolerance: nausea, vomiting, constipation, diarrhoea or reflux can affect what and how much someone eats. Side effects need careful handling, not simply “pushing through”. [1]
• Starting weight and health profile: baseline weight, type 2 diabetes, sleep apnoea, pain, mobility, menopause, mental health, other medicines and previous weight loss attempts can all affect progress.
• Nutrition quality: very low appetite can make it harder to get enough protein, fibre and fluids. Under-eating can also make fatigue, constipation and muscle loss more likely.
• Activity and muscle: walking, daily movement and light resistance work can support fat loss, fitness and muscle retention, even when appetite is lower.
• Consistency: missed doses, interrupted supply, changing injection days incorrectly or stopping and restarting can change the pattern of response. [1]

This is why average weight loss on Mounjaro is useful, but only up to a point. The trial figures help set expectations. Your own treatment decisions should be based on your response, side effects, clinical history and prescriber review.

Is Mounjaro better than Wegovy for weight loss?

Searches often compare Mounjaro with Wegovy, Ozempic and other GLP-1 medicines. For weight management, the most relevant comparison is usually tirzepatide with semaglutide 2.4 mg, because semaglutide 2.4 mg is the dose used in Wegovy.

In SURMOUNT-5, tirzepatide produced greater average weight loss than semaglutide 2.4 mg at 72 weeks: 21.6% compared with 15.4%. [1] NICE also notes that indirect comparisons suggest tirzepatide is more effective than semaglutide alongside diet and exercise support. [3]

That should not be turned into a simple “best medicine” claim. Averages do not replace clinical suitability. Side effects, contraindications, supply, previous treatment, dose tolerance, medical history, other medicines, pregnancy planning and patient preference all matter.

Why before-and-after photos and reviews are a poor way to judge your likely result

Before-and-after images, success stories and online reviews can be persuasive, but they are not a safe way to predict your own result. They often leave out starting BMI, dose, duration, side effects, diet quality, activity, health conditions, support, medication interruptions and what happened after the photo or review.

A clinical trial average is not perfect either, but it is a better starting point because the timeframe, population and outcome measures are defined. For this topic, the most useful public answer is not to look at dramatic transformations; it is “here is what controlled evidence shows, and here is why your own result may differ”.

What if you are not losing weight on Mounjaro?

Not losing weight on Mounjaro is a common concern. It can feel frustrating, especially when public discussion focuses on dramatic results. The right response is to look for the clinical and practical reasons before assuming the treatment has failed.

• Check the stage of treatment. If you are still in the first month, you are usually on the introductory dose. [1]
• Look at the weight trend, not one weigh-in. A 4-week average is usually more useful than a single day.
• Review appetite and intake. Very small portions are not automatically better if protein, fibre and fluids have dropped too low.
• Check side effects. Constipation, nausea, diarrhoea and vomiting can change weight, appetite and hydration. Persistent or severe symptoms need review. [1]
• Check the injection routine. Missed doses and altered schedules can affect response. Do not move to every-other-week dosing or change dose without clinical advice. [1]
• Review other factors. Sleep, alcohol, stress, pain, mobility, menopause, diabetes, steroid use, antidepressants and other medicines can all affect weight change.

A plateau can also happen after earlier success. Weight loss naturally becomes harder as body weight falls, because the body has less mass to maintain and appetite signals can adapt. That does not make the plateau a personal failure. It means the plan needs a more careful review.

How to support Mounjaro weight loss results safely

Mounjaro is not a replacement for nutrition, movement, sleep and support. It can make some changes easier by reducing hunger and food noise, but the aim is not to eat as little as possible. The aim is to lose weight while protecting health, muscle, energy and long-term habits.

• Build meals around protein first, especially when appetite is low. This can help protect muscle during weight loss.
• Use simple fibre sources such as vegetables, pulses, wholegrains, fruit, nuts and seeds where tolerated. Increase gradually if constipation is an issue.
• Keep fluids steady, particularly if nausea, vomiting or diarrhoea occur. Gastrointestinal side effects can increase dehydration risk. [1]
• Add manageable movement rather than punishing exercise. Walking, short strength sessions and daily mobility can be more sustainable than aggressive training plans.
• Track waist, symptoms, appetite, energy and medication tolerance as well as weight. The scales are important, but they are not the only useful data.
• Raise side effects early. Dose escalation is not a race, and tolerability matters.

Side effects and when to speak to a prescriber

The most commonly reported adverse reactions with tirzepatide are gastrointestinal. The SmPC says nausea, diarrhoea and vomiting occur mainly during dose escalation and tend to decrease over time. In pooled SURMOUNT-1 and SURMOUNT-2 weight-management studies, gastrointestinal disorders were reported in about 55.6% to 55.8% of tirzepatide groups, compared with 29.7% with placebo; most were mild or moderate. [1]

You should also speak to a prescriber if vomiting or diarrhoea is repeated, you cannot keep fluids down, you feel faint or dehydrated, side effects are affecting eating and drinking, or you are considering changing your dose or dosing schedule. The SmPC gives specific missed-dose instructions; self-directed changes are not a safe substitute for clinical advice. [1]

Can Mounjaro results be maintained?

Weight maintenance is part of the licensed weight-management indication, not an afterthought. The official indication includes weight loss and weight maintenance as an adjunct to reduced-calorie diet and increased physical activity. [1]

SURMOUNT-4 is relevant here. After an initial tirzepatide treatment period, people who continued treatment lost more weight from week 36 to week 88, while those switched to placebo regained weight on average. [1] That does not mean everyone must remain on treatment indefinitely, but it does show why stopping, pausing or changing treatment should be planned rather than improvised.

A sensible long-term plan should cover dose, side effects, nutrition, activity, weight trend, health markers, mental load, medication access and what to do if appetite increases again.

What the latest UK guidance means

UK medicine information, MHRA authorisation and NICE guidance all point in the same broad direction: tirzepatide can be effective for weight management in suitable adults, but it should be used with diet and activity support and within clinical eligibility criteria. [1] [2] [3]

NICE recommends tirzepatide as an NHS option for adults with an initial BMI of at least 35 kg/m2 and at least one weight-related comorbidity, with lower BMI thresholds for some ethnic backgrounds. NICE also sets a 6-month review point if less than 5% of initial weight has been lost after titrating to the highest tolerated dose. [3]

NHS England is implementing access in phases. Private prescribing and NHS prescribing are not the same access route, but both should still be assessment-led and clinically appropriate. [3] [4]